These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 29730603)

  • 1. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
    Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
    Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
    Boden EK; Shows DM; Chiorean MV; Lord JD
    Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of αEβ7 integrin suppresses accumulation of CD8
    Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
    Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases.
    Rath T; Billmeier U; Ferrazzi F; Vieth M; Ekici A; Neurath MF; Atreya R
    Front Immunol; 2018; 9():1700. PubMed ID: 30131801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
    Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
    J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.
    Lynch KD; Chapman RW; Keshav S; Montano-Loza AJ; Mason AL; Kremer AE; Vetter M; de Krijger M; Ponsioen CY; Trivedi P; Hirschfield G; Schramm C; Liu CH; Bowlus CL; Estes DJ; Pratt D; Hedin C; Bergquist A; de Vries AC; van der Woude CJ; Yu L; Assis DN; Boyer J; Ytting H; Hallibasic E; Trauner M; Marschall HU; Daretti LM; Marzioni M; Yimam KK; Perin N; Floreani A; Beretta-Piccoli BT; Rogers JK; ; Levy C
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):179-187.e6. PubMed ID: 31100458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D Is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.
    Gubatan J; Rubin SJS; Bai L; Haileselassie Y; Levitte S; Balabanis T; Patel A; Sharma A; Sinha SR; Habtezion A
    J Crohns Colitis; 2021 Dec; 15(12):1980-1990. PubMed ID: 34180967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
    Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
    J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.
    Jovani M; Danese S
    Curr Drug Targets; 2013 Nov; 14(12):1433-43. PubMed ID: 23980911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
    J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
    Scribano ML
    World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD.
    Liu H; Dasgupta S; Fu Y; Bailey B; Roy C; Lightcap E; Faustin B
    BMC Immunol; 2019 Nov; 20(1):42. PubMed ID: 31718550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal α4β7+ Lymphocytes and MAdCAM+ Venules Predict Response to Vedolizumab in Ulcerative Colitis.
    Roosenboom B; Wahab PJ; Smids C; Meijer J; Kemperman LGJM; Groenen MJM; van Lochem EG; Horjus Talabur Horje CS
    Inflamm Bowel Dis; 2024 Jun; 30(6):930-938. PubMed ID: 37436917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A product review of vedolizumab in inflammatory bowel disease.
    Battat R; Dulai PS; Jairath V; Vande Casteele N
    Hum Vaccin Immunother; 2019; 15(10):2482-2490. PubMed ID: 30897022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
    Zwicker S; Lira-Junior R; Höög C; Almer S; Boström EA
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab Efficacy Is Associated With Decreased Intracolonic Dendritic Cells, Not Memory T Cells.
    Boden EK; Kongala R; Hindmarch DC; Shows DM; Juarez JG; Lord JD
    Inflamm Bowel Dis; 2024 May; 30(5):704-717. PubMed ID: 37837660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.